Errors in Table 2 and Figure 2

In the Original Investigation titled “Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial,”¹ published in December 2019, there were errors in Table 2 and Figure 2. In Table 2, the table header “30 mg (n = 45)” in the fourth column should have cited table note “b,” not “a.” In Figure 2, panels B and C should have been labeled “Percentage change in EASI” and “Patients with ≥4-point improvement in pruritis NRS score,” respectively. This article was corrected online.